An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ultragenyx Pharmaceutical Inc. reports the grant of 44,965 restricted stock units to newly hired non-executive officers under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan. The restricted stock units vest over four years, with 25% of the shares vesting annually.
Ultragenyx Pharmaceutical Inc. ha annunciato l'assegnazione di 44.965 unità di azioni vincolate a nuovi ufficiali non esecutivi assunti sotto la Regola 5635(c)(4) del Nasdaq. Le assegnazioni sono state approvate dal comitato compensi e concesse nell'ambito del Piano di Induzione all'Assunzione di Ultragenyx. Le unità di stock vincolate matureranno nel corso di quattro anni, con il 25% delle azioni che diventeranno effettive annualmente.
Ultragenyx Pharmaceutical Inc. informa sobre la concesión de 44,965 unidades de stock restringido a oficiales no ejecutivos recién contratados bajo la Regla de Listado 5635(c)(4) de Nasdaq. Los premios fueron aprobados por el comité de compensaciones y otorgados bajo el Plan de Inducción de Empleo de Ultragenyx. Las unidades de stock restringido se otorgarán en un período de cuatro años, con el 25% de las acciones liberándose anualmente.
울트라제넥스 파마슈티컬 인크가 나스닥 상장 규칙 5635(c)(4)에 따라 새롭게 고용된 비집행 임원들에게 44,965개의 제한 주식 단위를 부여했다고 보고했습니다. 이 상은 보상 위원회의 승인을 받았으며 울트라제넥스 취업 유인 계획 하에 부여되었습니다. 제한 주식 단위는 4년에 걸쳐 조건이 충족되며, 매년 25%의 주식이 해제됩니다.
Ultragenyx Pharmaceutical Inc. rapporte l'octroi de 44 965 unités d'actions restreintes à de nouveaux officiers non-exécutifs embauchés selon la Règle de cotation Nasdaq 5635(c)(4). Les attributions ont été approuvées par le comité de rémunération et accordées dans le cadre du Plan d'Incitation à l'Emploi d'Ultragenyx. Les unités d'actions restreintes seront acquises sur quatre ans, avec 25% des actions se libérant annuellement.
Ultragenyx Pharmaceutical Inc. berichtet über die Zuteilung von 44.965 Restricted Stock Units an neu eingestellte nicht-geschäftsführende Beamte nach der Nasdaq Listing Rule 5635(c)(4). Die Vergaben wurden vom Vergütungsausschuss genehmigt und im Rahmen des Ultragenyx Employment Inducement Plan gewährt. Die Restricted Stock Units werden über vier Jahre hinweg erworben, wobei jährlich 25% der Anteile übertragen werden.
Positive
None.
Negative
None.
NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Investors & Media Joshua Higa (415) 475-6370
FAQ
How many restricted stock units were granted by Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. granted 44,965 restricted stock units to 14 newly hired non-executive officers.
Under which Nasdaq listing rule were the restricted stock units granted?
The restricted stock units were granted under Nasdaq Listing Rule 5635(c)(4) by Ultragenyx Pharmaceutical Inc.
What is the vesting period for the restricted stock units?
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date.
When was the grant date for the restricted stock units?
The grant date for the restricted stock units was April 16, 2024.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
